

**Jared Probst, M.D.**  
CCT Research  
1910 S Stapley Drive, Suite 120  
Mesa, AZ 85204

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, VP Sponsor Relations/BD  
Apex Innovative Sciences, Alliance Division  
Tel. 916-803-7149 (cell)  
Email: bobbietheodore@apexsci.com

**AFFILIATIONS:**

South Ogden Family Practice/Ogden Clinic/CCT Research  
5740 Crestwood Drive  
South Ogden, UT 84405

Olympus Family Medicine/ CCT Research  
4624 Holladay Blvd E  
Salt Lake City, UT 84117

**EDUCATION:**

1996 MD  
University of Utah School of Medicine, Salt Lake City, Utah

1992 BS Sociology  
Utah State University, Logan, Utah

**LICENSURE:**

Utah - Physician - License Number: 373445-1205  
Utah - Physician CS - License Number: 373445-8905

**RESIDENCY:**

1996-1999 Family Practice  
Medical College of Wisconsin, Milwaukee, Wisconsin

**CERTIFICATION:**

American Board of Family Medicine – Certified

**PROFESSIONAL EXPERIENCE:**

*Principal Investigator*, 2020 – present  
CCT Research, Utah

*Principal Investigator*, 2016 – 2020  
Accelerated Enrollment Solutions (formerly Synexus Clinical Research), Holladay, Utah

*Family Practice Physician*, 1999 – Present  
Olympus Family Medicine, Holladay, Utah

*Emergency Physician*, 1998 – 1999  
St. Nicholas Hospital, Sheboygan, Wisconsin

*Urgent Care Physician*, 1997 – 1999  
St. Mary's Clinic, Milwaukee, Wisconsin

*Volunteer Physician*, 1997 – 1999  
Isaac Cogg Homeless Clinic, Milwaukee, Wisconsin

**INVESTIGATOR EXPERIENCE:**

COVID-19 Diagnostic Studies • COVID-19 Treatment Studies • Influenza • Type 2 Diabetes

**ADDITIONAL INTEREST:**

Acne and Atopic Dermatitis • Allergy • Angina • Ankle Sprain • Anxiety • Arrhythmia • Arthritis  
Asthma • Atrial Fibrillation • Cardiovascular Device • Congestive Heart Failure  
Coronary Artery Disease • Depression • Type 1 Diabetes • Diabetic Neuropathy  
Diabetic Retinopathy • Diabetic Nephropathy • GERD • Gout • Hyperlipidemia • Hypertension  
Irritable Bowel Syndrome • Lateral Epicondylitis (tennis elbow) • Metabolic Syndrome • Obesity  
Osteoporosis • Otitis Media • Overactive Bladder • Pain Management • Parkinson's Disease  
Pediatric Diabetes • Pediatric Hypercholesterolemia • Pediatric Hypertension  
Rheumatoid Arthritis • Sexual Dysfunction • Sexually Transmitted Disease • Smoking Cessation  
Tinea Pedis (Athlete's Foot) • Thyroid Disorders • Ulcerative Colitis • Women's Health Studies  
Vaccines (COVID and other) • Oncology • Other Internist Indications

**CLINICAL TRIAL EXPERIENCE:**

**COVID-19**

A Phase II, Multicenter Adaptive Randomized Double-Blind Placebo Controlled Platform Trial of the Efficacy and Safety of XXX in COVID-19 Adults not Requiring Hospitalization at Time of Diagnosis

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase II, Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of XXX in Adults With Mild COVID-19 Symptoms

A Diagnostic Clinical Performance Validation of XXX , SARS-CoV-2 (COVID-19) Rapid Antigen Detection Assay, in the Point of Care Setting

A Phase II, Randomized, Double blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-Coronavirus Response of Suppression of XXX in Out-patient Adults with SARS-CoV-2 (The XXX Study)

An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of XXX in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting

A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of XXX in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19

Clinical Evaluation of the XXX COVID-19 Ag AnTigen (Ag) Assay in Symptomatic Subjects (CATSS)

***Influenza***

A Multicenter Study Conducted to Evaluate the Performance of the XXX Flu A&B Assay at Point of Care Testing Sites

***Type 2 Diabetes***

A 52 Week Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety Of XXX Compared To XXX Or Placebo Added To XXX In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy

A 26 Week Randomized, Double-Blind, Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety Of XXX Compared To XXX, And Placebo In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control On Dipeptidyl Peptidase 4 Inhibiter (DPP41) With Or Without Metformin

A 56 Week, Multicenter, Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of XXX Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise

**CLINICAL TRIAL EXPERIENCE (*continued*):**

*Vaccines*

A Phase III, Randomized, Active-controlled, Observer-blinded Trial to Assess the Safety, Tolerability, and Immunogenicity of XXX in Healthy Participants  $\geq 10$  to  $< 26$  Years of Age